Form 4: Glaukos Director Weisner Receives Equity Compensation

Director Aimee S. Weisner acquired 1,878 restricted stock units and 2,987 stock options as part of the Glaukos Corporation director compensation policy.

Summary

• Director Aimee S. Weisner was granted 1,878 restricted stock units (RSUs) on May 28, 2026.
• The director also received a grant of 2,987 stock options with an exercise price of $53.57.
• The RSUs and options vest in full on the one-year anniversary of the grant date (May 28, 2027).
• Following these transactions, the director holds 20,684 shares directly, with additional indirect holdings through family trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance or outlook.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.
• The grants are part of a standard, pre-established director compensation policy.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Future share price volatility could impact the value of the granted equity instruments.
• Vesting is contingent upon continued service as a director.

Future Outlook

The equity grants are subject to a one-year vesting period, indicating the director's continued involvement with the company through at least May 2027.

Management Comments

• The grants were issued pursuant to the Issuer's Director Compensation Policy.

Industry Context

StockSavvy.ai notes that standard equity-based compensation for board members is a common practice in the medical device industry to ensure governance alignment with corporate performance.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is consistent with standard corporate governance practices for mid-cap medical technology companies.
• The one-year vesting schedule is typical for annual director equity refresh grants.

Corporate Governance

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of equity awards on May 28, 2027.

Key Dates

Keywords

Glaukos, GKOS, Form 4, Director Compensation, Insider Trading, Equity Grant